Lycia Therapeutics raised $106M in a Series C financing led by Venrock Healthcare Capital Partners for the development of lysosomal targeting chimeras (lytacs) to treat autoimmune and inflammatory diseases.
PUBLIC · LYCAMay 13, 2024
Amount Raised
$106 Million
Round Type
Series C
South San FranciscoBiotechnology
Investors
Franklin TempletonMarshall WaceJanus Henderson InvestorsVenrock Healthcare Capital Partners
Description
Lycia Therapeutics, a startup based in South San Francisco, raised $106 million in a Series C financing led by Venrock Healthcare Capital Partners. The funding will advance the research and development of lysosomal targeting chimeras (lytacs) aimed at treating autoimmune and inflammatory diseases.
Who to call at Lycia Therapeutics, Inc., and when
A new round usually means Lycia Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Lycia Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Lycia Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lycia Therapeutics, Inc.. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Lycia Therapeutics, Inc.
Location
400 East Jamie Court, Suite 200
South San Francisco, California, United States
About
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lycia Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnology